Optimal Response in a Patient With CML Expressing BCR–ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report

Background/Aim: The Philadelphia chromosome is considered the hallmark of chronic myeloid leukemia (CML). However, although most patients with CML are diagnosed with the e13a2 or e14a2 breakpoint cluster region (BCR)–Abelson 1 (ABL1) fusion transcripts, about 5% of them carry rare BCR–ABL1 fusion tr...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :In Vivo
Главные авторы: MANZELLA, LIVIA, TIRRÒ, ELENA, VITALE, SILVIA RITA, PUMA, ADRIANA, CONSOLI, MARIA LETIZIA, TAMBÈ, LOREDANA, PENNISI, MARIA STELLA, DI GREGORIO, SANDRA, ROMANO, CHIARA, TOMARCHIO, CRISTINA, DI RAIMONDO, FRANCESCO, STAGNO, FABIO
Формат: Artigo
Язык:Inglês
Опубликовано: International Institute of Anticancer Research 2020
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7279803/
https://ncbi.nlm.nih.gov/pubmed/32354950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11933
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы